Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$95.95 +2.7%	$94.46	$79.52 ▼ $124.00	$24.26B	1.36	893,257 shs	1.37 million shs
MRNA Moderna	$47.19 -0.8%	$50.24	$22.28 ▼ $59.55	$18.88B	1.05	7.61 million shs	6.31 million shs
NVAX Novavax	$10.97 +6.3%	$8.86	$6.13 ▼ $11.97	$1.70B	2.37	6.30 million shs	7.15 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$148.98B	0.35	33.36 million shs	48.26 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+2.69%	+4.14%	-5.53%	-12.95%	-1.62%
MRNA Moderna	-0.80%	+0.66%	+3.22%	-11.91%	+81.15%
NVAX Novavax	+6.30%	+19.11%	+37.64%	+8.19%	+58.53%
PFE Pfizer	+0.11%	+1.02%	-0.32%	-5.16%	+12.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$95.95 +2.7%	$94.46	$79.52 ▼ $124.00	$24.26B	1.36	893,257 shs	1.37 million shs
MRNA Moderna	$47.19 -0.8%	$50.24	$22.28 ▼ $59.55	$18.88B	1.05	7.61 million shs	6.31 million shs
NVAX Novavax	$10.97 +6.3%	$8.86	$6.13 ▼ $11.97	$1.70B	2.37	6.30 million shs	7.15 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$148.98B	0.35	33.36 million shs	48.26 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+2.69%	+4.14%	-5.53%	-12.95%	-1.62%
MRNA Moderna	-0.80%	+0.66%	+3.22%	-11.91%	+81.15%
NVAX Novavax	+6.30%	+19.11%	+37.64%	+8.19%	+58.53%
PFE Pfizer	+0.11%	+1.02%	-0.32%	-5.16%	+12.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$129.56	35.03% Upside
MRNA Moderna	1.84	Reduce	$35.73	-24.28% Downside
NVAX Novavax	2.10	Hold	$12.13	10.53% Upside
PFE Pfizer	2.20	Hold	$28.82	10.08% Upside

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2026	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00
5/27/2026	BNTX BioNTech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$117.00 ➝ $135.00
5/26/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
5/21/2026	BNTX BioNTech	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$96.00
5/21/2026	BNTX BioNTech	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/12/2026	BNTX BioNTech	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$155.00 ➝ $140.00
5/7/2026	NVAX Novavax	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/6/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$171.00 ➝ $158.00
5/6/2026	BNTX BioNTech	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$150.00 ➝ $140.00

(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.81B	8.65	$1.37 per share	69.99	$86.54 per share	1.11
MRNA Moderna	$2.20B	8.50	N/A	N/A	$18.67 per share	2.53
NVAX Novavax	$1.12B	1.61	$3.73 per share	2.94	($0.88) per share	-12.47
PFE Pfizer	$62.58B	2.38	$4.40 per share	5.95	$15.86 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$5.88	N/A	N/A	N/A	-44.39%	-5.30%	-4.62%	8/3/2026 (Estimated)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	7/31/2026 (Estimated)
NVAX Novavax	$440.30M	-$0.58	N/A	N/A	N/A	-14.73%	-14.82%	1.23%	8/5/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.99	9.15	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest NVAX, PFE, MRNA, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVAX Novavax	-$0.25	-$0.06	+$0.19	-$0.06	$79.81 million	$118.90 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
5/4/2026	Q1 2026	BNTX BioNTech	-$2.52	-$2.2570	+$0.2630	-$2.43	$207.42 million	$136.71 million
5/1/2026	Q1 2026	MRNA Moderna	-$3.02	-$3.40	-$0.38	-$3.40	$236.37 million	$389.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.59%	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.57%	-13.20%	131.30%	16 Years

Latest NVAX, PFE, MRNA, and BNTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.80	8.74
MRNA Moderna	0.08	2.41	2.35
NVAX Novavax	N/A	2.48	2.45
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
MRNA Moderna	10.80%
NVAX Novavax	1.00%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable
NVAX Novavax	1,990	164.44 million	162.79 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

NVAX, PFE, MRNA, and BNTX Headlines

Recent News About These Companies

Pfizer Pivots to Obesity and Oncology as Wall Street Waits

4 hours ago | tipranks.com

Mailbag: A Follow-Up on Pfizer & Other Questions

May 30 at 9:22 AM | etftrends.comE

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30 at 8:38 AM | finance.yahoo.com

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30 at 8:00 AM | businesswire.com

Pfizer Inc. $PFE Shares Bought by Triglav Investments D.O.O.

May 30 at 7:18 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Koss Olinger Consulting LLC

May 30 at 6:44 AM | marketbeat.com

Norges Bank Purchases New Position in Pfizer Inc. $PFE

May 30 at 6:44 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Forsta AP Fonden

May 30 at 4:31 AM | marketbeat.com

Fideuram Asset Management Ireland dac Takes $2.11 Million Position in Pfizer Inc. $PFE

May 30 at 4:08 AM | marketbeat.com

Amica Mutual Insurance Co. Has $5.05 Million Stake in Pfizer Inc. $PFE

May 30 at 3:23 AM | marketbeat.com

Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging

May 29 at 7:11 PM | finance.yahoo.com

Arvinas to Present at Jefferies Global Healthcare Conference

May 29 at 7:11 PM | finance.yahoo.com

Insiders Aren’t Buying Pfizer Stock at $26 and That’s Actually a Good Thing

May 29 at 5:30 PM | finance.yahoo.com

Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal

May 29 at 2:10 PM | finance.yahoo.com

Pfizer’s Real-World Lung Cancer Study on Dacomitinib: What Investors Should Know

May 29 at 12:50 PM | tipranks.com

Pfizer’s MET097 Obesity Trial Reaches Key Milestone: What Investors Should Watch Next

May 29 at 12:50 PM | tipranks.com

Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market

May 29 at 12:50 PM | tipranks.com

Can AI crack pharma’s drug repurposing goldmine?

May 29 at 9:09 AM | pharmavoice.comP

Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal

May 29 at 9:09 AM | pharmaceutical-technology.comP

Pfizer and Innovent Biologics sign $10.5B cancer drug deal

May 29 at 9:09 AM | qz.comQ

Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29 at 9:09 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVAX, PFE, MRNA, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

$95.95 +2.51 (+2.69%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$96.00 +0.05 (+0.05%)

As of 05/29/2026 07:59 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna NASDAQ:MRNA

$47.19 -0.38 (-0.80%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$47.36 +0.17 (+0.35%)

As of 05/29/2026 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$10.97 +0.65 (+6.30%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$10.94 -0.04 (-0.32%)

As of 05/29/2026 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$26.18 +0.04 (+0.16%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$26.15 -0.03 (-0.13%)

As of 05/29/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVAX, PFE, MRNA, and BNTX Earnings

Compare Dividends

Latest NVAX, PFE, MRNA, and BNTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVAX, PFE, MRNA, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVAX, PFE, MRNA, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVAX, PFE, MRNA, and BNTX Earnings

Compare Dividends

Latest NVAX, PFE, MRNA, and BNTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVAX, PFE, MRNA, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVAX, PFE, MRNA, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools